Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.76 |
| ▸ | MAP2K1 | Q02750 | 9/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327100 | 0.89 | RAF1 (0.82) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6327310 | 0.88 | RAF1 (0.80) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL5584957 | 0.87 | RAF1 (1.00) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6326868 | 0.82 | RAF1 (0.79) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6324891 | 0.81 | RAF1 (0.80) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6324552 | 0.79 | RAF1 (0.73) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6324830 | 0.78 | SLC2A1 (0.53) | RAF1MAP2K1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6324574 | 0.78 | RAF1 (0.80) | RAF1MAP2K1ALDH1A1KDM4ETDP1 | |
| SCHEMBL6324928 | 0.77 | RAF1 (0.82) | RAF1MAP2K1ALDH1A1KDM4EAPP | |
| SCHEMBL6324701 | 0.75 | RAF1 (0.69) | RAF1MAP2K1ALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE | 2005-10-13 | — | — | US | disclosed |
| EP-1442018-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037865-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | TP53, ABCG2, MCL1 | RAF1 660/4885MAP2K1 4672/4885ALDH1A1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.